Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

November 2022 | 79 pages | ID: M36D2D8E43A3EN
Global Markets Direct

Abstracts

Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Drugs In Development, 2022, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape.

Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Macular Edema - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 3, 4, 4, 2 and 11 respectively.

Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Macular Edema (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Macular Edema (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Macular Edema (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Macular Edema (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Macular Edema (Ophthalmology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Macular Edema (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Macular Edema (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Macular Edema - Overview
Macular Edema - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Macular Edema - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Macular Edema - Companies Involved in Therapeutics Development
3SBio Inc
Aerie Pharmaceuticals Inc
AsclepiX Therapeutics Inc
Celon Pharma SA
Clearside BioMedical Inc
Clonz Biotech Pvt Ltd
Coherus BioSciences Inc
F. Hoffmann-La Roche Ltd
Huadong Medicine Co Ltd
Luye Pharma Group Ltd
Mabion SA
Novartis AG
Oculis SA
PharmAbcine Inc
Polus Inc
Prestige BioPharma Ltd
Profarma
Ripple therapeutics Corp
Shilpa Medicare Ltd
Sustained Nano Systems LLC
Taiwan Liposome Co Ltd
Targeted Therapy Technologies LLC
Tarsius Pharma Ltd
Tiantai Yinkang Biological Medicine Co Ltd
Macular Edema - Drug Profiles
601A anti-VEGF Ab - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
AXT-107 - Drug Profile
Product Description
Mechanism Of Action
celecoxib - Drug Profile
Product Description
Mechanism Of Action
dexamethasone acetate - Drug Profile
Product Description
Mechanism Of Action
dexamethasone sodium phosphate SR 1 - Drug Profile
Product Description
Mechanism Of Action
dexamethasone SR - Drug Profile
Product Description
Mechanism Of Action
dexamethasone XR - Drug Profile
Product Description
Mechanism Of Action
faricimab - Drug Profile
Product Description
Mechanism Of Action
IBI-304 - Drug Profile
Product Description
Mechanism Of Action
MHU-650 - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibodies to Inhibit VEGF for Age Related Macular Degeneration and Macular Edema - Drug Profile
Product Description
Mechanism Of Action
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
ranibizumab SR - Drug Profile
Product Description
Mechanism Of Action
triamcinolone acetonide - Drug Profile
Product Description
Mechanism Of Action
TRS-02 - Drug Profile
Product Description
Mechanism Of Action
Macular Edema - Dormant Projects
Macular Edema - Discontinued Products
Macular Edema - Product Development Milestones
Featured News & Press Releases
Sep 19, 2022: Coherus to launch CIMERLI (ranibizumab-eqrn) in the United States on October 3, 2022
Aug 02, 2022: FDA approves Coherus' CIMERLI (ranibizumab-eqrn) as the first and only interchangeable biosimilar to Lucentis for all five indications, with 12 months of interchangeability exclusivity
Jul 07, 2022: Clearside Biomedical suprachoroidal delivery technology to be featured at upcoming ASRS and OIS Medical Meetings
Jul 06, 2022: Bausch + Lomb announces scientific data on XIPERE (Triamcinolone Acetonide Injectable Suspension) to be presented during the American Society of Retina Specialists Annual Scientific Meeting
May 05, 2022: Clearside Biomedical poster presentation on XIPERE at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technology
Mar 28, 2022: Bausch + Lomb and Clearside Biomedical announce the U.S. commercial launch of XIPERE (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal use for the treatment of macular edema associated with uveitis
Nov 23, 2021: Arctic Vision starts dosing with ARVN001 in macular oedema trial
Nov 16, 2021: Clearside Biomedical features FDA-approved XIPERE in multiple presentations at the American Academy of Ophthalmology 2021 and American Uveitis Society Meetings
Oct 26, 2021: Sansheng Guojian's anti-VEGF monoclonal antibody 601A (ophthalmology) CRVO project phase IIa clinical trial was completed and subjects were enrolled
Oct 25, 2021: FDA approves Bausch + Lomb and Clearside’s macular oedema treatment
Oct 06, 2021: Aerie Pharmaceuticals announces presentation at the 39th Annual Scientific Meeting of the American Society of Retina Specialists
Jun 02, 2021: Bausch Health and Clearside Biomedical announce U.S. FDA filing acceptance for XIPERE (triamcinolone acetonide suprachoroidal injectable suspension)
May 10, 2021: Clearside Biomedical announces poster presentation on XIPERE at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting
May 03, 2021: Clearside Biomedical announces resubmission of new drug application for XIPERE for treatment of macular edema associated with uveitis
Feb 08, 2021: Clearside Biomedical presented data on XIPERE at the 44th Virtual Annual Macula Society Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Macular Edema, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Macular Edema - Dormant Projects, 2022
Macular Edema - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Macular Edema, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022